Calquence 欧盟 - 瑞典文 - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Nasoferm Mentol 1 mg/ml Nässpray, lösning 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

nasoferm mentol 1 mg/ml nässpray, lösning

nordic drugs ab - xylometazolinhydroklorid - nässpray, lösning - 1 mg/ml - makrogolglycerolhydroxistearat hjälpämne; xylometazolinhydroklorid 1 mg aktiv substans; bensalkoniumklorid hjälpämne

Ophthajod 50 mg/ml Ögondroppar, lösning 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

ophthajod 50 mg/ml ögondroppar, lösning

vital pharma nordic aps - povidon, joderad - Ögondroppar, lösning - 50 mg/ml - povidon, joderad 50 mg aktiv substans; glycerol hjälpämne

Nezebi 0,25 mg/ml Nässpray, lösning 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

nezebi 0,25 mg/ml nässpray, lösning

perrigo sverige ab - oximetazolinhydroklorid - nässpray, lösning - 0,25 mg/ml - oximetazolinhydroklorid 0,25 mg aktiv substans

Nezeril Dexpantenol 0,25 mg/ml Nässpray, lösning 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

nezeril dexpantenol 0,25 mg/ml nässpray, lösning

perrigo sverige ab - oximetazolinhydroklorid - nässpray, lösning - 0,25 mg/ml - oximetazolinhydroklorid 0,25 mg aktiv substans

Epysqli 欧盟 - 瑞典文 - EMA (European Medicines Agency)

epysqli

samsung bioepis nl b.v. - eculizumab - hemoglobinuri, paroxysmal - immunsuppressiva - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Tyruko 欧盟 - 瑞典文 - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Perindopril arginine Actavis 10 mg Filmdragerad tablett 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

perindopril arginine actavis 10 mg filmdragerad tablett

actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 10 mg - laktosmonohydrat hjälpämne; perindoprilarginin 10 mg aktiv substans

Perindopril arginine Actavis 2,5 mg Filmdragerad tablett 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

perindopril arginine actavis 2,5 mg filmdragerad tablett

actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; perindoprilarginin 2,5 mg aktiv substans

Perindopril arginine Actavis 5 mg Filmdragerad tablett 瑞典 - 瑞典文 - Läkemedelsverket (Medical Products Agency)

perindopril arginine actavis 5 mg filmdragerad tablett

actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; perindoprilarginin 5 mg aktiv substans